Loading
A prospective blinded study showing how well the ThyroSeq v3 test sorted thyroid nodules whose needle sample was uncertain.
The classifier had 94 per cent (95% CI 86 to 98) sensitivity and 82 per cent (95% CI 75 to 87) specificity, with a negative predictive value of 97 per cent.
A negative result makes cancer unlikely enough that some people can avoid diagnostic surgery.
Shares Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Biomarker, Thyroid cancer.
Shares Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Biomarker, Thyroid cancer.
Shares ThyroSeq v3 Genomic Classifier, Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Thyroid cancer.
Shares ThyroSeq v3 Genomic Classifier, Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Thyroid cancer.
Shares Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Thyroid cancer.
Shares Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Thyroid cancer.
Shares Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Thyroid cancer.
Shares Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Thyroid cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/